Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$110.94 USD

110.94
7,458,602

+1.05 (0.96%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

AmerisourceBergen (ABC) Q2 Earnings Beat, Revenues Miss

AmerisourceBergen's (ABC) Q2 earnings gain from solid segmental performance and higher adjusted operating income growth. But contraction in adjusted gross and operating margins remains a dampener.

Amedisys (AMED) Tops Earnings and Revenue Estimates in Q1

At Home Health and Hospice divisions, Amedisys (AMED) witnesses solid year-over-year growth in Medicare and non-Medicare revenues.

ABIOMED (ABMD) Q4 Earnings Meet Estimates, Sales Rise in Japan

ABIOMED's (ABMD) Q4 results gain from solid Impella show in Japan.

Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall

Hologic (HOLX) registers solid Q1year-over-year revenue growth in core businesses like Breast Health and Molecular Diagnostics.

CVS Health's (CVS) Q1 Earnings Top Estimates, EPS View Up

Year-over-year growth in CVS Health's (CVS) top line is aided by a strong Pharmacy Services segment, benefiting from the upside in specialty services.

IDEXX (IDXX) Q1 Earnings Top Estimates, EPS Guidance Up

Strong sales at the CAG business favor IDEXX's (IDXX) top line in Q1.

Tandem's (TNDM) Q1 Loss Wider Than Expected, Sales Top Mark

Tandem's (TNDM) introduction of t:slim X2 with Basal-IQ technology, ramped-up supply capacity along with its global launch, substantially drive its top line in Q1.

Urmimala Biswas headshot

LabCorp (LH) Q1 Earnings Top Mark, Revenues Lag Estimates

Despite increasing acquisitions and favorable mix, the disposition of certain businesses and the implementation of PAMA are adversely affecting LabCorp's (LH) growth.

Chemed (CHE) Q1 Earnings Miss Estimates, Revenues Grow Y/Y

Despite several downsides, Chemed (CHE) witnesses solid revenue growth across key subsidiaries - VITAS and Roto-Rooter.

Ecolab (ECL) Earnings Beat, Revenues Miss Estimates in Q1

Ecolab (ECL) gains from core Global Industrial and Global Institutional segments in Q1.

Hill-Rom's (HRC) Earnings and Revenues Top Estimates in Q2

The strong Q2 performance of Hill-Rom (HRC) is backed by solid core revenue growth, continued margin expansion and strategic investments.

Top Ranked Income Stocks to Buy for April 29th

Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 29th

Urmimala Biswas headshot

Zimmer Biomet's (ZBH) Q1 Earnings, Revenues Beat Estimates

While sales in Americas remains dull, Zimmer Biomet (ZBH) is witnessing strength in the Asia Pacific and EMEA regions.

Integra LifeSciences (IART) Q1 Earnings Beat, Margins Rise

Integra LifeSciences' (IART) quarterly performance is majorly hurt by the company's exit from the transition services agreements covering Western Europe.

Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Up

Illumina's (ILMN) NextSeq and MiSeq placements witness year-over-year growth, with the strength of the former being driven by solid demand for TSO500.

GNC Holdings (GNC) Reports Q1 Earnings, Revenues Down Y/Y

Despite year-over-year decline in earnings and revenues, better performing International segment and key developments favor GNC Holdings (GNC) in Q1.

PerkinElmer (PKI) Beats on Q1 Earnings, Hikes '19 Guidance

PerkinElmer's (PKI) Q1 earnings gain from top-line growth, solid show by Diagnostics segment and strong margins. However, negative currency movement remains a headwind.

Omnicell (OMCL) Earnings and Revenues Beat Estimates in Q1

Omnicell (OMCL) gains from solid segmental contributions in Q1; margins expand.

Cerner (CERN) Earnings and Revenues Meet Estimates in Q1

Cerner (CERN) gains from Professional Services unit in first-quarter 2019. A decline in bookings raises concern.

Zacks.com featured highlights include: PepsiCo, Raymond James, Kansas City Southern, Fortive and Abbott Laboratories

Zacks.com featured highlights include: PepsiCo, Raymond James, Kansas City Southern, Fortive and Abbott Laboratories

Varian (VAR) Q2 Earnings Lag Estimates, Gross Orders Surge

Varian (VAR) gains from solid segmental contributions in Q2, raises revenue guidance.

Align Technology (ALGN) Beats on Q1 Earnings, Margins Down

Align Technology (ALGN) reports promising top-line numbers on double-digit increase in Invisalign case shipments from a year ago.

Swayta Shah headshot

Solid Sales Growth Makes These 5 Stocks Worth Buying Now

Sales growth is an early indicator of the company's future earnings performance.

Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?

Is (ABT) Outperforming Other Medical Stocks This Year?

Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid

Abbott (ABT) reports strong and consistent EPD and Medical Devices performance organically in Q1.